Effects of prenatal small-quantity lipid-based nutrient supplements on pregnancy, birth and infant outcomes: a systematic review and meta-analysis of individual participant data from randomized controlled trials in low- and middle-income countries

Kathryn G. Dewey, K. Ryan Wessells, Charles D. Arnold, Seth Adu-Afarwuah, Benjamin F. Arnold, Per Ashorn, Ulla Ashorn, Ana Garcés, Lieven Huybregts, Nancy F. Krebs, Anna Lartey, Jef L. Leroy, Kenneth Maleta, Susana L. Matias, Sophie E. Moore, Malay K. Mridha, Harriet Okronipa, Christine P. Stewart

Institute for Global Nutrition and Department of Nutrition, University of California, Davis, Davis, CA, USA (KGD, KRW, CDA, CPS)

Department of Nutrition and Food Science, University of Ghana, Legon, Accra, Ghana (SAA, AL)

Francis I. Proctor Foundation, University of California, San Francisco, San Francisco, CA, USA (BFA)

Center for Child, Adolescent and Maternal Health Research, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland (PA, UA)

Department of Paediatrics, Tampere University Hospital, Tampere, Finland (PA)

Proyecto Salud y Nutrición, Jhpiego, Guatemala City, Guatemala (AG)

Poverty, Health, and Nutrition Division, International Food Policy Research Institute, Washington, DC, USA (LH, JL)

Section of Nutrition, Department of Pediatrics, University of Colorado School of Medicine, Denver, CO, USA (NFK)

Department of Nutrition and Dietetics, School of Global and Public Health, Kamuzu University of Health Sciences, Blantyre, Malawi (KM)

Department of Nutritional Sciences and Toxicology, University of California, Berkeley,

Berkeley, CA, USA (SLM)

Department of Women & Children's Health, King's College London, London, UK and MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Fajara, The Gambia (SEM)

Center for Non-communicable Diseases and Nutrition, BRAC James P Grant School of Public Health, Bangladesh (MKM)

Department of Nutritional Sciences, Oklahoma State University, Stillwater, OK, USA (HO)

Corresponding Author: Kathryn G. Dewey, Department of Nutrition, University of California, One Shields Ave., Davis, CA 95616; 530 752 0851; kgdewey@ucdavis.edu

Sources of Support: Bill & Melinda Gates Foundation OPP49817. The funder had no role in the design, implementation, analysis or interpretation of the data.

Short running head: Effects of prenatal SQ-LNS

Abbreviations: BEP, balanced energy protein; BMIZ, body mass index-for-age z-score; EFA, essential fatty acids; GRADE, Grading of Recommendations Assessment, Development and Evaluation; HCGAZ, head circumference-for-gestational age z-score; HCZ, head circumferencefor-age z-score; IFA, iron and folic acid supplement; IPD, individual participant data; IRB, institutional review board; LAZ, length-for-age z-score; LBW, low birth weight; LMIC, low-

and middle-income countries; LGA, large-for-gestational age; LGAZ, length-for-gestational age z-score; LNS, lipid-based nutrient supplements; LQ-LNS, large-quantity lipid-based nutrient supplements; MD, mean difference; MMS, multiple micronutrient supplement; MQ-LNS, medium-quantity lipid-based nutrient supplements; MUAC, mid-upper arm circumference; MUACZ, mid-upper arm circumference z-score; PR, prevalence ratio; RCT, randomized controlled trial; RR, relative risk; SAP, statistical analysis plan; SGA, small-for-gestational age; SOC, standard of care; SQ-LNS, small-quantity lipid-based nutrient supplements; SVN, small vulnerable newborn; WAZ, weight-for-age z-score; WGAZ, weight-for-gestational age z-score; WLZ, weight-for-length z-score.

Registry and registry number for systematic reviews or meta-analyses: Registered at www.crd.york.ac.uk/PROSPERO as CRD42021283391 on 11 April 2021.

Data described in the manuscript, code book, and analytic code will not be made available because they are compiled from 4 different trials, and access is under the control of the investigators of each of those trials.

Dr. Nancy Krebs is on the Editorial Board of the American Journal of Clinical Nutrition and played no role in the Journal's evaluation of the manuscript.

Abstract

- Conclusions: SQ-LNS had positive impacts on multiple outcomes compared to IFA/SOC, but
- further research directly comparing SQ-LNS and MMS is needed. Targeting SQ-LNS to
- vulnerable subgroups may be worth considering. Analysis registered at
- www.crd.york.ac.uk/PROSPERO (CRD42021283391).
- Keywords: Maternal nutrition, low birthweight, preterm birth, fetal growth restriction, balanced
- energy protein supplementation, antenatal interventions, infant wasting, infant stunting

Introduction

 Undernutrition is prevalent among women of reproductive age globally, with an estimated 1.2 billion deficient in one or more micronutrients (1), 571 million (30%) with anemia (2-4), and 170 33 million $(\sim 10\%)$ being underweight $(3, 4)$. As a result, many women and girls enter pregnancy with nutritional deficits. The risk of undernutrition during pregnancy is exacerbated by the elevated nutrient needs to support gestation, particularly in low- and middle-income countries (LMICs) where diets are often inadequate in multiple nutrients (5). This situation contributes to poor maternal health and the risk of giving birth to a small vulnerable newborn (SVN), an umbrella term that encompasses small-for-gestational age (SGA), preterm birth, and low birthweight (LBW) (6). In 2020, 26.2% of all livebirths globally were SVNs, with 16.3% SGA, 8.8% preterm, and 1.1% both SGA and preterm (7). Although poor nutrition is not the only cause of these outcomes (8), interventions to improve maternal nutrition, such as multiple micronutrient supplements (MMS) and balanced energy-protein supplementation (BEP) for undernourished mothers, should be considered critical elements of antenatal care packages aimed at reducing SVN births (9). Lipid-based nutrient supplements (LNS) provide multiple micronutrients embedded in a food base that also provides energy, protein and fat. LNS for pregnant women are a type of BEP, as they meet the criterion that protein contributes < 25% of the energy content (10). The intended daily ration of LNS can be small- medium- or large-quantity (SQ-, MQ- or LQ-LNS) (11). Maternal SQ-LNS was designed to fill nutrient gaps during pregnancy and the first 6 mo postpartum with a daily ration of only 20 g (118 kcal/d) (11), which minimizes cost and potential displacement of home-prepared foods. SQ-LNS is not primarily designed to fill energy gaps, as

such gaps can be filled by more affordable local foods (11). SQ-LNS provides several key

 nutrients not provided by iron and folic acid (IFA) supplements or MMS, including essential fatty acids (EFAs) as well as calcium, magnesium, potassium, and phosphorus (11). This combination of macro- and micro-nutrients addresses multiple potential nutritional deficiencies and thus can reduce maternal undernutrition. Maternal SQ-LNS is currently being distributed by USAID in selected food aid programs (12), but its use is not yet widespread. A previous meta-analysis of maternal LNS (13) demonstrated that LNS given during pregnancy, compared to IFA, had positive effects on birth weight, length, duration of gestation, SGA, and newborn stunting. That meta-analysis included 3 trials, all of which used SQ-LNS. In a separate comparison of LNS vs MMS that also included 3 trials (2 SQ-LNS, 1 MQ-LNS), there were no significant differences in birth outcomes (13). More recently, Hunter et al. (14) conducted a meta-analysis of maternal LNS vs MMS that included 4 trials (2 SQ-LNS, 1 MQ-LNS, 1 LQ- LNS); they found a significant reduction in LBW but not preterm birth or SGA. The authors of these previous meta-analyses did not have individual participant data (IPD) and thus were not able to examine individual-level effect modification. Effect modification analysis can provide important insights regarding the potential for participants to benefit from an intervention, as well as their potential to respond (15). These 2

 concepts reflect different attributes, with potential to benefit most likely related to greater deficits at baseline, and potential to respond related to lack of constraints on exhibiting an improvement in the outcome due to factors such as infection or inflammation. In some cases, individuals with greater potential to benefit may also have a lower potential to respond, which can limit the beneficial impact of an intervention. Identification of subgroups of pregnant women with the greatest potential to benefit from or respond to LNS can help inform decisions regarding targeting. We conducted an IPD meta-analysis of randomized controlled trials (RCTs) of SQ-

 LNS provided to pregnant women that had 2 objectives: 1) to compare overall effects of SQ- LNS with provision of a) IFA or standard of care (IFA/SOC) or b) MMS, and 2) examine potential effect modifiers of the impact of SQ-LNS (as compared to either IFA/SOC or MMS) on birth outcomes.

Methods

The protocol for this systematic review and IPD meta-analysis was prospectively registered on

PROSPERO (CRD42021283391) (16). The statistical analysis plan (SAP) is available on Open

84 Science Framework [\(https://osf.io/nj5f9/\)](https://osf.io/nj5f9/) (17) and was posted prior to analysis. The protocol was

reviewed by the institutional review board (IRB) of the University of California, Davis and

determined to be exempt from IRB approval given that protocols for each individual trial had

been previously approved by their respective ethical committees.

Inclusion and exclusion criteria for this IPD meta-analysis

We included prospective randomized controlled trials of maternal SQ-LNS that met the

following study-level inclusion criteria: 1) trial was conducted in a low- or middle-income

country (18), 2) maternal SQ-LNS (~125 kcal/d) was provided for at least part of pregnancy to

intervention group participants, 3) comparison group(s) received iron and folic acid (IFA),

multiple micronutrient supplements (MMS) (defined below) or standard of care (SOC), 4) trial

reported at least one outcome of interest (defined below), and 5) trial used an individual or

cluster randomized design in which the same participants were measured at baseline and endline

(longitudinal follow-up) or different participants were measured at baseline and endline

IPD integrity

 We conducted a complete-case intention-to-treat analysis (21). We evaluated whether the study sample sizes in our pooled data set were the same as in study protocols and publications. To address missing outcome data, we tabulated the percentage of participants lost to follow-up between enrollment and the assessment of the outcomes for each study. We also assessed whether missing data were differential with respect to intervention group by comparing rates of missingness across randomized arms.

 We flagged biologically implausible values. For anthropometric outcomes, we calculated z- scores using the 2006 WHO child growth standards (22, 23) and the INTERGROWTH standards (24), checked the values for acceptable SDs, and flagged implausible values if they were outside of published WHO acceptable ranges (22, 23). Implausible values were inspected for errors and either winsorized (25) if within 2 SD of the WHO acceptable ranges or removed from analysis if clearly impossible on an outcome-by-outcome basis. Such cleaning was necessary for <0.2% of participants. There was a consistently low rate of implausibility across outcomes and studies. We also checked summary statistics from the harmonized data-set (e.g., means and SDs) against each trial's published values.

Assessment of risk of bias in each study and quality of evidence across studies

Two independent reviewers (KRW and CDA) assessed risk of bias in each trial against the

- following criteria: random sequence generation and allocation concealment (selection bias),
- blinding of participants and personnel (performance bias), blinding of outcome assessment
- (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias), and

 For continuous outcomes, the principal measure of effect was the mean difference (MD) between intervention and comparison groups; for binary outcomes it was the relative risk (RR) for birth outcomes and adverse outcomes, and the prevalence ratio (PR; relative difference in proportions between groups) for anthropometric outcomes at 6 mo of age. We also estimated the effect for binary outcomes as the absolute differences between intervention groups in events per 1000 individuals. The absolute differences are useful for assessing public health impact, but we considered them secondary outcomes because they can be less consistent than RRs or PRs across studies (26).

 The comparisons of interest were 1) SQ-LNS vs IFA/SOC and 2) SQ-LNS vs MMS. Study arms in which SQ-LNS began prior to conception were excluded from the main analyses because the objectives were to evaluate effects of SQ-LNS when given during pregnancy; however, the pre-conception study arms were included in sensitivity analyses.

Synthesis methods and exploration of variation in effects

Guatemala study was one of 4 sites in the Women First trial (35). In that trial, an unfortified LNS

(in addition to SQ-LNS) supplying 300 kcal/d was provided to intervention group women who

were either underweight or who had inadequate gestational weight gain. In 3 of the 4 study sites

(Democratic Republic of the Congo, India, and Pakistan), >90% of enrolled women in the

intervention groups received this supplement in addition to SQ-LNS, so the total amount of LNS

256 provided to them was \sim 418 kcal/d, which would be categorized as MQ-LNS rather than SQ-

 LNS. Therefore, only the Guatemala site is included in these analyses (where < 10% of enrolled women received the unfortified LNS in addition to SQ-LNS).

 All 4 trials provided data for the comparison of SQ-LNS vs IFA/SOC; in 3 trials IFA was provided to this comparison group (32-34), and in 1 trial (Guatemala) the comparison group received SOC (biweekly visits to monitor pregnancy status) (35). Two of the 4 trials (Ghana and Malawi) also included an arm that received MMS and thus provided data for the comparison of SQ-LNS vs MMS (33, 34). In Ghana and in the "complete follow-up" cohort in Malawi (who received supplementation beyond pregnancy, see Table 1), SQ-LNS and MMS were provided until 6 mo postpartum and IFA was provided until delivery followed by placebo (low dose calcium) until 6 mo postpartum; in the "simplified follow-up" cohort in Malawi (supplementation only during pregnancy), SQ-LNS, MMS or IFA were provided only until delivery (33, 34). In Bangladesh, SQ-LNS was provided until 6 mo postpartum and IFA until 3 mo postpartum (32), and in Guatemala, SQ-LNS was provided only until delivery (35). The nutrient composition of SQ-LNS was nearly identical across trials (**Supplemental Table 1)**, except for more vitamin D and less zinc in the version used in Guatemala. The MMS used in Ghana and Malawi was a formulation designed to match the micronutrient content of the SQ- LNS (11), which was based in part on results of a trial in Guinea-Bissau (36) that demonstrated a 275 greater impact on birth weight when the MMS contained $2X$ (vs $1X$) the recommended dietary allowance of most of the nutrients (except for iron, folic acid and vitamin A). Thus, the MMS used in Ghana and Malawi had higher levels of most of the micronutrients compared to the United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) (37).

Figure 1). All trials had a high risk of bias for blinding of participants, as blinding was not

incomplete outcome, selective reporting, and "other" (**Supplemental Table 6** and **Supplemental**

possible given the physical difference in the supplements provided.

SQ-LNS vs IFA/SOC

Main effects

- For most birth outcomes, all 4 trials contributed to the pooled effect estimates and the total
- sample size was 4,922-5,348 (**Table 2**). For continuous birth outcomes based on
- INTERGROWTH-21st standards, we excluded participants without ultrasound data, as
- mentioned above, and as a result only 3 trials contributed to the estimates for WGAZ, LGAZ and
- HCGAZ (total n ~1,460-1,717).
- Maternal SQ-LNS had a significant positive effect on all of the continuous birth outcomes, with
- 312 a MD compared to IFA/SOC of +49 g for birth weight, +0.2 cm for birth length, +0.10-0.13 z-
- scores for WAZ, WGAZ, LAZ, LGAZ, BMIZ, HCZ, and HCGAZ, +0.08 cm for MUAC, and
- $314 +0.12$ wk for duration of gestation. Maternal SQ-LNS reduced the risk of LBW by 11%,
- newborn stunting by 17%, low BMIZ by 11%, and low HCZ by 11%. Effect estimates for the
- other binary birth outcomes were not statistically significant but were in the same direction
- (except for LGA, RR 1.00 (0.61, 1.65)).

 We rated the quality of the evidence for all birth outcomes as moderate based on the GRADE criteria listed in the Methods: 3-4 RCTs were available for all outcomes, risk of bias was low except for blinding of participants, heterogeneity was low, precision was rated as high because all trials had sample sizes > 400, all trials were directly aimed at evaluating SQ-LNSs, and funnel plots revealed no indication of publication bias.

 In general, there was consistency across studies in the direction of effects, with very low heterogeneity based on I2 values (**Figures 2A-F** for birth weight, LBW, newborn LAZ, newborn

 HCZ, newborn BMIZ and duration of gestation; **Supplemental Figures 2A-BM** for all 326 outcomes). Low I^2 values may be attributable to relatively wide CIs for some of the point estimates rather than low variability in the RRs. For nearly all outcomes, fixed effects and random-effects models generated identical estimates. With regard to the sensitivity analyses, no trials had a high level of missingness of outcome data, so no sensitivity analyses for that reason were needed. When including only ultrasound dating for outcomes dependent on gestational age (which excluded the Bangladesh trial), the magnitude of the effect estimates increased but effects remained non-significant: RR=0.86 (0.73, 1.01) for SGA (n=1,717), MD=0.15 (-0.03, 0.33) for duration of gestation (n=1,880) and RR=0.90 (0.68, 1.18) for preterm birth (n=1,880) (**Supplemental Table 7A**). For the other sensitivity analyses, restricting birth size outcomes to data collected within 72 h of birth, or excluding the Guatemala trial (in which some women received additional LNS), or including the pre-conception arm of the Guatemala trial, there was very little change in the findings. For most of the effects of SQ-LNS vs IFA/SOC on anthropometric outcomes at 6 mo of age, all 340 4 trials contributed to the pooled estimates and the total sample size was \sim 5,030; outcomes based on MUACZ were not available for Guatemala (**Table 3)**. Maternal SQ-LNS reduced underweight at 6 mo (PR 0.85 (0.73, 0.99)), but effects on the other outcomes were not

 statistically significant. In sensitivity analyses, the PR for underweight became non-significant when Guatemala was excluded (0.96 (0.80, 1.16)) (with or without exclusion of the "simplified follow-up" cohort in Malawi; in this cohort and in Guatemala, maternal supplementation did not continue after delivery). The PR for underweight was not strengthened when the pre-conception

 arm was included for Guatemala (0.90 (0.78, 1.13)). For other outcomes, these sensitivity analyses did not substantively alter the findings (**Supplemental Table 7B**).

 There were no significant differences in any of the adverse outcomes for the SQ-LNS vs IFA/SOC comparison, and the RR was generally < 1 except for incidence of stillbirths (**Table 4**). Because of uncertainty in gestational age dating, it is sometimes difficult to distinguish between miscarriage and stillbirths (i.e., before vs. after 28 wk gestation), and in low resource settings it can also be difficult to differentiate between stillbirth and early neonatal death (34). For these reasons, Table 4 includes comparisons for 2 composite variables for these outcomes (miscarriage or stillbirth; miscarriage or stillbirth or early neonatal mortality). The RRs for those composite adverse outcomes were both < 1.0. Adverse outcome findings were similar in the sensitivity analyses (**Supplemental Table 7C**).

Effect modification by individual-level characteristics

361 For several characteristics, the p-for-interaction was > 0.10 for all or almost all infant birth outcomes, i.e., effect modification was generally not evident for child birth order, maternal height, education, or anemia at baseline, gestational age at start of supplementation, compliance with supplementation, household socio-economic status or sanitation (see **Supplemental Figures 3A-N** for results stratified by all characteristics**)**. For 5 characteristics, the p-for- interaction was < 0.10 for at least 2 birth outcomes, and data from at least 3 trials were available (**Figures 3A-J** show 12 selected birth outcomes for each of these characteristics, though the number of outcomes for which p-for-interaction was < 0.10 varied). The estimated effects of maternal SQ-LNS on birth outcomes were greater among a) female (vs. male) infants, for birth

 We explored whether the greater effect of SQ-LNS on birth size outcomes among females (vs. males) could be attributed mainly to the mediating effects on duration of gestation: when 394 including duration of gestation in the models, the p-for-interaction was > 0.10 for birth weight, 395 WAZ, BMIZ and HCZ but remained < 0.10 for LBW, birth weight < 2 kg, and low BMIZ (available at https://osf.io/nj5f9/(17)). Some of the above characteristics also modified the effect estimates for maternal SQ-LNS vs. IFA/SOC with respect to infant anthropometric outcomes at 6 mo, particularly infant sex. Effect

estimates were larger for females than for males, as was the case for the birth outcomes (**Figure**

4). Among females, maternal SQ-LNS was associated with a 26% reduction in underweight and

a 30% reduction in low HCZ, whereas there was no reduction among males. These findings were

very similar in the sensitivity analyses excluding Guatemala (with or without exclusion of the

"simplified follow-up" cohort in Malawi) (available at https://osf.io/nj5f9/ (17)). For 3 other

characteristics, the p-for-interaction was < 0.10 for at least 2 distinct infant outcomes at 6 mo.

Effect estimates for maternal SQ-LNS were greater among a) women with greater food

insecurity, for LAZ and underweight at 6 mo (**Supplemental Figures 3M3-4**); b) women with

improved sanitation, for WAZ and WLZ at 6 mo (**Supplemental Figure 3N3**); and c) later-born

children, for underweight and stunting at 6 mo (**Supplemental Figure 3B4**).

 Supplemental Figures 4A-N present pooled estimates for adverse outcomes, stratified by potential individual-level effect modifiers. For many of the potential effect modifiers, the p-for- interaction was > 0.10 for all of the adverse outcomes; for several other potential effect modifiers, the p-for-interaction was < 0.10 for only one adverse outcome, and for that outcome the difference between SQ-LNS and IFA/SOC groups was not significant in either subgroup. For

birth order, the p-for-interaction was < 0.10 for 2 outcomes: neonatal mortality and mortality 0-6

- mo. In both cases, the stratum-specific estimates were not significant: neonatal and 0-6 mo
- mortality RRs were respectively 0.54 (0.27, 1.06) and 0.60 (0.32, 1.15) among first-born infants,
- and 1.08 (0.69, 1.70) and 1.22 (0.86, 1.73) among later-born infants. These results were similar
- 418 in the sensitivity analyses (available at https://osf.io/nj5f9/ (17)).

SQ-LNS vs MMS

- *Main effects*
- Effects of SQ-LNS vs MMS on birth outcomes are based on 2 trials and a total sample size of
- 1,121-1,539 (**Table 5**). There were marginally significant differences in head circumference
- (+0.14 (-0.02, 0.31) cm) and HCGAZ (+0.11 (-0.01, 0.23)) favoring the SQ-LNS group, but p-
- 424 values for all other outcomes were > 0.10 . There was low heterogeneity, and fixed effects and
- random-effects models generated nearly identical estimates (**Figures 5A-C** and **Supplemental**
- **Figures 5A-AF**). We rated the quality of the evidence for all outcomes as low because data were
- available for only 2 trials, both conducted in Africa.
- Most of the pre-planned sensitivity analyses were not applicable to these 2 trials, except for the
- 429 one restricting birth size outcomes to data collected within 72 h of birth. In that sensitivity
- analysis, there was little change in the results except that the MDs for head circumference (+0.21
- (-0.03, 0.45)) and HCGAZ (+0.16 (-0.01, 0.34)) became larger (though still marginally

significant).

 Table 6 shows that there were no significant effects of SQ-LNS vs MMS on anthropometric outcomes at 6 mo of age. Findings were not altered when excluding the "simplified cohort

follow-up" in Malawi. **Table 7** shows no significant differences in adverse outcomes for the SQ-

LNS vs MMS comparison.

Effect modification by individual-level characteristics

 For most characteristics, the p-for-interaction was > 0.10 for all infant birth outcomes, i.e., effect modification was not evident for maternal height, BMI, education, or anemia at baseline, gestational age at start of supplementation, compliance with supplementation, household socio- economic status, food insecurity, or sanitation (**Supplemental Figures 6A-M**). The p-for- interaction was < 0.10 for at least 1 birth size outcome for 5 characteristics: child sex, birth order, maternal age, inflammation at baseline, and malaria at baseline. Effect modification estimates for maternal SQ-LNS vs MMS were greater (p-for-interaction < 0.10) among a) female (vs. male) infants for head circumference, HCZ, birth weight < 2 kg, SGA, low BMIZ and low HCZ (Supplemental Figures 6A1-2), b) first-born (vs. later-born) infants for birth weight and WAZ (Supplemental Figure 6B1), and c) younger women (< 25 vs. > 25 y) for SGA (Supplemental Figure 6E). Effect modification by maternal inflammation was difficult to interpret: effect estimates for maternal SQ-LNS vs. MMS were greater among women with inflammation for birth weight, but greater among those without inflammation for HCZ and HCGAZ (Supplemental Figure 6H1). Results for effect modification by maternal malaria were not interpretable because they could not be confirmed in the sensitivity analysis restricted to anthropometric outcomes measured within 72 h of birth, due to insufficient sample sizes in the subgroup with malaria at enrollment. Results of the sensitivity analysis restricted to birth size measured within 72 h for effect modification by child sex, birth order and maternal age are available at https://osf.io/nj5f9/ (17); the findings were similar but for some outcomes the sample sizes in certain subgroups were insufficient to generate effect estimates.

Discussion

 In this IPD meta-analysis, data from 4 trials showed that maternal SQ-LNS, compared to IFA or SOC, increased mean birth weight, length, head circumference, BMIZ, MUAC and duration of gestation, and on average reduced the incidence of LBW by 11%, newborn stunting by 17%, newborn wasting (low BMIZ) by 11%, and small head size (low HCZ) by 15%. Only 2 trials directly compared maternal SQ-LNS and MMS; birth outcomes did not differ significantly between these groups, although there was a marginally significant difference in newborn head circumference. Several individual-level characteristics appeared to modify the impact of maternal SQ-LNS. For the comparison with IFA or SOC, effect estimates for SQ-LNS were 475 greater among female infants and among women with BMI \leq 20 kg/m², inflammation or malaria at enrollment, or greater household food insecurity. For the comparison with MMS, effect estimates for SQ-LNS were greater among female infants, first-born infants, and women < 25 y of age. Some of these findings may have implications with regard to potential targeting of SQ-LNS to vulnerable women, as discussed below.

Main effects on birth outcomes and adverse outcomes

For SQ-LNS vs MMS, we cannot directly compare our estimated main effects to those of Das et

al. (13) because their analysis included 1 MQ-LNS trial in addition to the 2 SQ-LNS trials that

- are in our IPD meta-analysis. Although neither meta-analysis showed significant differences in
- birth outcomes between (SQ-)LNS and MMS groups, the MDs for all of the birth size outcomes
- in our IPD analysis were in the same direction as those for the SQ-LNS vs IFA/SOC analysis,

SQ-LNS vs IFA/SOC

The impact of SQ-LNS was greater among female than among male infants for many of the birth

outcomes. Among females, effect estimates for SQ-LNS suggested reductions of 20% for LBW,

Similarly, effects of SQ-LNS were greater among infants of women with inflammation or

malaria at enrolment. For inflammation, the p-for-interaction was significant for WAZ, duration

are at greater risk of nutrient inadequacy.

Effects of SQ-LNS on birth size outcomes tended to be greater among infants of mothers who

564 consumed supplements ≥ 4 days/wk than in those with lower compliance, although the p-for-

interaction was significant only for stunting. Among women with higher compliance, effect

estimates for SQ-LNS suggested reductions of 16% for LBW, 22% for newborn stunting, 14%

567 for newborn wasting, and 18% for small head size.

Effect modification was generally not evident for other maternal characteristics. This could be

important, as it suggests that a response to maternal SQ-LNS is not constrained by short maternal

stature, low education, anemia at baseline, later gestational age at start of supplementation, or

SQ-LNS vs MMS

As was found for the comparison of SQ-LNS vs IFA/SOC, effect estimates for SQ-LNS vs MMS

were greater among female than among male infants. The p-for-interaction with infant sex was

significant for several outcomes (HCZ, SGA, birth weight < 2 kg, low BMIZ, and small head

size), and the effect estimates for SQ-LNS were significant among females for LGAZ (+0.17

(0.00, 0.33)), HCZ (+0.21 (0.01, 0.40)) and HCGAZ (+0.19 (0.02, 0.37)). It is noteworthy that

these differences between intervention groups among females are for outcomes that reflect linear

growth and head size, and may be attributable to the differences in nutrient content between SQ-

LNS and MMS, particularly EFAs (important for brain development) (48) and minerals such as

calcium, potassium and magnesium (important for linear growth).

Effects of SQ-LNS vs MMS appeared to be greater among first-born than among later-born

infants. The p-for-interaction was significant for birth weight and WAZ, and among first-born

591 infants the effect estimates for SQ-LNS were substantial for birth weight $(+120 (35, 205)$ g) and

HCZ (+0.31 (0.05, 0.58)). However, there was heterogeneity between the 2 sites for this

 interaction, with results being driven by greater effects of SQ-LNS among first-born infants in Ghana but not in Malawi.

595 Effects of SQ-LNS on SGA were more beneficial among younger women than among those > 25

y, and there was a similar pattern for other birth outcomes. Among infants of younger mothers,

effect estimates for SQ-LNS vs MMS were significant for birth weight (+69 (4, 135)), WAZ

(+0.16 (0.01, 0.31)), and HCZ (+0.20 (0.00, 0.40)). This could reflect a greater potential to

benefit among infants of younger mothers (who are also more likely to be first-born), among

whom improved intake of EFAs and certain minerals could be more critical.

Effects on anthropometric status at 6 mo

 An important biological and programmatic question is whether prenatal supplementation has a sustained impact on infant growth status after birth. Previous evidence on this question has been mixed (49). In this meta-analysis, maternal SQ-LNS (compared to IFA or SOC) reduced the prevalence of underweight at 6 mo of age by 15%, but effects on the other anthropometric outcomes were not statistically significant. Among female infants, underweight at 6 mo was reduced by 26%, whereas no effect was observed among male infants. In 3 cohorts (Bangladesh, Ghana and half of the Malawi cohort), mothers continued to receive supplements after delivery for up to 6 mo, so it is possible that some of the impact on infant underweight at 6 mo is attributable to postpartum effects, e.g., through breast milk composition or maternal caregiving capacity. However, when we excluded the two cohorts in which mothers did not continue to receive supplements postpartum (Guatemala and half of the Malawi cohort), the effect estimate for underweight was weaker rather than stronger, suggesting that the reduction in underweight is likely related to SQ-LNS received prenatally. This is an important finding because underweight among infants is a key risk factor for mortality (50-52).

 There were no significant differences in infant anthropometric status at 6 mo in the comparison of SQ-LNS vs MMS.

Strengths and limitations

 Strengths of this IPD meta-analysis include the high quality of the randomized controlled trials contributing to the estimates, data from diverse settings on 3 different continents, and the consistency in findings between fixed-effects and random-effects models as well as in most of the sensitivity analyses. Limitations include the relatively small number of trials (especially for the SQ-LNS vs MMS comparison), and limited statistical power to detect differences in rare outcomes. Results of the effect modification analyses should be interpreted with caution because many of the potential effect modifiers are interrelated and also may be confounded by other unmeasured factors. In addition, there was variation in the methods used in each study to assess certain potential effect modifiers such as household food insecurity and socio-economic status.

Conclusions and implications

 Maternal SQ-LNS has substantial positive effects on birth outcomes when compared with IFA or SOC, especially among female infants and among vulnerable women such as those with low BMI, inflammation or malaria at enrollment, or greater household food insecurity. Provision of SQ-LNS to pregnant women may also reduce the prevalence of underweight among infants at 6 mo of age. An important programmatic question is whether maternal SQ-LNS is superior to MMS, which is lower in cost and is currently being scaled-up (53, 54). Based on this meta- analysis as well as the meta-analyses of MMS (19, 38), we conclude that SQ-LNS and MMS have similar positive effects on birth weight outcomes when comparing each with IFA.

biomarkers of inflammation at enrollment on several different metrics of fetal growth (ponderal,

- linear and head size) is noteworthy, given that the percentage of women in this subgroup was
- 40.8% in Ghana, 45.9% in Malawi and 16.6% in Bangladesh (this information was not available

 for Guatemala). These findings suggest a greater potential to benefit from maternal SQ-LNS among such women. The mechanisms underlying these findings require further investigation. Further research is also needed to elucidate potential biological explanations for the stronger effects of maternal SQ-LNS observed among female infants, compared to males, and how to overcome the constraints on response among males. Regardless of the mechanism, the substantial reduction in risk of newborn stunting among females may have implications with regard to subsequent height during childhood, adolescence and adulthood (55, 56). Greater maternal stature in females at the time of childbearing may reduce the risk of SGA and thereby help prevent the intergenerational transmission of impaired growth. From a programmatic perspective, the effects among vulnerable subgroups demonstrated herein suggest that targeting provision of SQ-LNS to younger women, those with low BMI, or those in households with food insecurity may be worth considering. This type of targeting is envisioned for BEP interventions in general (9), and the 2016 WHO guideline on antenatal care (57) already recommends prenatal BEP in populations with a high prevalence of undernutrition among pregnant women. Given that SQ-LNS meets the definition of BEP, our results support the strategy of targeting food-based supplements to pregnant women who have the greatest potential to benefit. SQ-LNS provides less energy than most BEP supplements that have been evaluated, but at present there is no clear dose-response relationship between the quantity of LNS (or BEP of other types) and birth outcomes (58). Further research is needed to identify the optimal energy content of LNS for pregnant women. However, it is noteworthy that the effects of SQ-LNS (vs IFA/SOC) on birth outcomes in this IPD analysis were larger among women with greater food insecurity, despite the small amount of energy provided. This implies that improving intake of essential nutrients during pregnancy in high-risk populations is of paramount importance.

Acknowledgments

- We thank all of the co-investigators, collaborators, study teams, participants and local
- communities involved in the trials included in these analyses. These trials benefitted from the
- contributions of many partner organizations, including: icddr,b (Rang-Din Nutrition Study); the
- International Lipid-based Nutrient Supplements Project Steering Committee (iLiNS Project
- trials); NICHD-Global Network for Women's and Children's Health Research and Institute of
- Nutrition in Central America and Panama (INCAP) (Women First trial); and Nutriset (for
- development of SQ-LNS).

- The authors' responsibilities were as follows—KGD: drafted the manuscript with input from
- KRW, CDA, CPS and other coauthors; KRW, CDA, KGD, and CPS: wrote the statistical
- analysis plan; BFA, PA, LH, NFK, JL, SM: reviewed, contributed to, and approved the statistical
- analysis plan; KRW and CDA: compiled the data; CDA: conducted the data analysis; and all
- authors: read, contributed to, and approved the final manuscript; KGD is responsible for final

content.

 Supported by Bill & Melinda Gates Foundation grant OPP49817 (to KGD). All authors report no conflicts of interest.

REFERENCES

- 1. Stevens G.A., Beal T., Mbuya M.N.N., Luo H., Neufeld L.M., Global Micronutrient Deficiencies Research G. Micronutrient deficiencies among preschool-aged children and women of reproductive age worldwide: a pooled analysis of individual-level data from population-representative surveys. Lancet Glob Health 2022;10:e1590-e9.
- 2. World Health Organization. Global Anaemia Estimates. 2021. Available at: https://www.who.int/data/gho/data/themes/topics/anaemia in women and children. Accessed on: 4 April 2022.
- 3. United Nations Children's Fund. UNICEF Programming Guidance. Prevention of malnutrition in women before and during pregnancy and while breastfeeding. New York: UNICEF, 2021. Available at:

https://www.unicef.org/media/114561/file/Maternal%20Nutrition%20Programming%20 Guidance.pdf. Accessed on: 18 March 2024.

- 4. United Nations Children's Fund. UNICEF Data: Monitoring the situation of children and women. Women's Nutrition. 2021. Available at: https://data.unicef.org/topic/nutrition/womens-nutrition/#resources. Accessed on: 18 March 2024.
- 5. Torheim L.E., Ferguson E.L., Penrose K., Arimond M. Women in resource-poor settings are at risk of inadequate intakes of multiple micronutrients. J Nutr 2010;140:2051S-8S.
- 6. Ashorn P., Ashorn U., Muthiani Y., Aboubaker S., Askari S., Bahl R., et al. Small vulnerable newborns-big potential for impact. Lancet 2023;401:1692-706.
- 7. Lawn J.E., Ohuma E.O., Bradley E., Idueta L.S., Hazel E., Okwaraji Y.B., et al. Small babies, big risks: global estimates of prevalence and mortality for vulnerable newborns to accelerate change and improve counting. Lancet 2023;401:1707-19.
- 8. Hunter P.J., Awoyemi T., Ayede A.I., Chico R.M., David A.L., Dewey K.G., et al. Biological and pathological mechanisms leading to the birth of a small vulnerable newborn. Lancet 2023;401:1720-32.
- 9. Hofmeyr G.J., Black R.E., Rogozinska E., Heuer A., Walker N., Ashorn P., et al. Evidencebased antenatal interventions to reduce the incidence of small vulnerable newborns and their associated poor outcomes. Lancet 2023;401:1733-44.
- 10. Ota E., Hori H., Mori R., Tobe-Gai R., Farrar D. Antenatal dietary education and supplementation to increase energy and protein intake. Cochrane Database of Systematic Reviews 2015:CD000032.
- 11. Arimond M., Zeilani M., Jungjohann S., Brown K.H., Ashorn P., Allen L.H., Dewey K.G. Considerations in developing lipid-based nutrient supplements for prevention of undernutrition: Experience from the International Lipid-Based Nutrient Supplements (iLiNS) Project. Matern Child Nutr 2015;11 31-61.
- 12. USAID Advancing Nutrition. Small-Quantity Lipid-Based Nutrient Supplement Program implementation learnings and considerations for scale-up from International Food Relief Partnership partners in Honduras, Niger, and Somalia. Arlington, VA: USAID Advancing Nutrition. 2022. Available at: https://www.advancingnutrition.org/resources/smallquantity-lipid-based-nutrient-supplement-program-implementation. Accessed on: 12 April 2023.
- 13. Das J.K., Hoodbhoy Z., Salam R.A., Bhutta A.Z., Valenzuela-Rubio N.G., Weise Prinzo Z., Bhutta Z.A. Lipid-based nutrient supplements for maternal, birth, and infant developmental outcomes. Cochrane Database of Systematic Reviews 2018;8:CD012610.

- 14. Hunter P.J., Muthiani Y., Nasanen-Gilmore P.K., Koivu A.M., Portfors P., Bastola K., et al. A modular systematic review of antenatal interventions to address undernutrition during pregnancy in the prevention of low birth weight. Amer J Clin Nutr 2023;117 Suppl 2:S134-S47.
- 15. Dewey K.G., Stewart C.P., Wessells K.R., Prado E.L., Arnold C.D. Small-quantity lipidbased nutrient supplements for the prevention of child malnutrition and promotion of healthy development: Overview of individual participant data meta-analysis and programmatic implications. Amer J Clin Nutr 2021;114:3S-14S.
- 16. Wessells R., Dewey K., Stewart C., Arnold C., Prado E. Modifiers of the effect of LNS provided to pregnant women on maternal, birth and infant outcomes: A systematic review and meta-analysis of individual participant data from randomized controlled trials in lowand middle-income countries. PROSPERO CRD42021283391. 2021. Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021283391 Accessed on: 18 March 2024..
- 17. Wessells K.R., Dewey K., Arnold C.D., Stewart C., Prado E. Modifiers of the effect of LNS provided to pregnant women on maternal, birth and infant outcomes. Open Science Framework. 2021. Available at: https://osf.io/nj5f9/. Accessed on: 18 March 2024.
- 18. World Bank Historical Classification by Income Group. Available at: http://databank.worldbank.org/data/download/site-content/OGHIST.xls Accessed on: 22 August 2019.
- 19. Smith E.R., Shankar A.H., Wu L.S., Aboud S., Adu-Afarwuah S., Ali H., et al. Modifiers of the effect of maternal multiple micronutrient supplementation on stillbirth, birth outcomes, and infant mortality: a meta-analysis of individual patient data from 17 randomised trials in low-income and middle-income countries. Lancet Glob Health 2017;5:e1090-e100.
- 20. WHO. WHO antenatal care recommendations for a positive pregnancy experience. Nutritional interventions update: Multiple micronutrient supplements during pregnancy. Geneva: World Health Organization, 2020.
- 21. Johnston B.C., Guyatt G.H. Best (but oft-forgotten) practices: intention-to-treat, treatment adherence, and missing participant outcome data in the nutrition literature. Am J Clin Nutr 2016;104:1197-201.
- 22. WHO Multicentre Growth Reference Study Group. WHO Child Growth Standards: Length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: Methods and development. Geneva: World Health Organization, 2006.
- 23. WHO Multicentre Growth Reference Study Group. WHO Child Growth Standards: Head circumference-for-age, arm circumference-for-age, triceps skinfold-for-age and subscapular skinfold-for-age: Methods and development. Geneva: World Health Organization, 2007.
- 24. Villar J., Cheikh Ismail L., Victora C.G., Ohuma E.O., Bertino E., Altman D.G., et al. International standards for newborn weight, length, and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of the INTERGROWTH-21st Project. Lancet 2014;384:857-68.
- 25. Tukey J. The future of data analysis. The Annals of Mathematical Statistics 1962;33:1-67.
- 26. Higgins J., Green S. Cochrane Handbook for Systematic Reviews for Interventions, Version 5.1.0. The Cochrane Collaboration 2011. Available from www.handbook.cochrane.org.

- 27. Balshem H., Helfand M., Schunemann H.J., Oxman A.D., Kunz R., Brozek J., et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64:401-6.
- 28. Dewey K.G., Wessells K.R., Arnold C.D., Prado E.L., Abbeddou S., Adu-Afarwuah S., et al. Characteristics that modify the effect of small-quantity lipid-based nutrient supplementation on child growth: An individual participant data meta-analysis of randomized controlled trials. Amer J Clin Nutr 2021;114 (Suppl 1):15S-42S.
- 29. Burke D.L., Ensor J., Riley R.D. Meta-analysis using individual participant data: one-stage and two-stage approaches, and why they may differ. Stat Med 2017;36:855-75.
- 30. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in metaanalyses. BMJ 2003;327:557-60.
- 31. Streiner D.L. Best (but oft-forgotten) practices: the multiple problems of multiplicity-whether and how to correct for many statistical tests. Am J Clin Nutr 2015;102:721-8.
- 32. Mridha M.K., Matias S.L., Chaparro C.M., Paul R.R., Hussain S., Vosti S.A., et al. Lipidbased nutrient supplements for pregnant women reduce newborn stunting in a clusterrandomized controlled effectiveness trial in Bangladesh. Amer J Clin Nutr 2016;103:236- 49.
- 33. Adu-Afarwuah S., Lartey A., Okronipa H., Ashorn P., Zeilani M., Peerson J.M., et al. Lipidbased nutrient supplement increases the birth size of infants of primiparous women in Ghana. Amer J Clin Nutr 2015;101:835-46.
- 34. Ashorn P., Alho L., Ashorn U., Cheung Y.B., Dewey K.G., Harjunmaa U., et al. The impact of lipid-based nutrient supplement provision to pregnant women on newborn size in rural Malawi: A randomized controlled trial. Amer J Clin Nutr 2015;101:387-97.
- 35. Hambidge K.M., Westcott J.E., Garces A., Figueroa L., Goudar S.S., Dhaded S.M., et al. A multicountry randomized controlled trial of comprehensive maternal nutrition supplementation initiated before conception: The Women First trial. Amer J Clin Nutr 2019;109:457-69.
- 36. Kaestel P., Michaelsen K.F., Aaby P., Friis H. Effects of prenatal multimicronutrient supplements on birth weight and perinatal mortality: a randomised, controlled trial in Guinea-Bissau. Eur J Clin Nutr 2005;59:1081-9.
- 37. The Multiple Micronutrient Supplement Technical Advisory Group (MMS-TAG), The Micronutrient Forum (MNF). Expert consensus on an open-access United Nations International Multiple Micronutrient Antenatal Preparation - multiple micronutrient supplement product specification. Annals New York Acad Sci 2020;1470:3-13.
- 38. Keats E.C., Haider B.A., Tam E., Bhutta Z.A. Multiple-micronutrient supplementation for women during pregnancy. Cochrane Database Syst Rev 2019;3:CD004905.
- 39. Wessells K.R., Arnold C.D., Stewart C.P., Prado E.L., Abbeddou S., Adu-Afarwuah S., et al. Characteristics that modify the effect of small-quantity lipid-based nutrient supplementation on child anemia and micronutrient status: an individual participant data meta-analysis of randomized controlled trials. Amer J Clin Nutr 2021;114:68S-94S.
- 40. Moore S.E. Sex differences in growth and neurocognitive development in infancy and early childhood. Proc Nutr Soc 2024:1-8.
- 41. Wells J.C. Natural selection and sex differences in morbidity and mortality in early life. J Theor Biol 2000;202:65-76.
- 42. Sauder M.W., Lee S.E., Schulze K.J., Christian P., Wu L.S.F., Khatry S.K., et al. Inflammation throughout pregnancy and fetal growth restriction in rural Nepal. Epidemiol Infect 2019;147:e258.

- 43. Desai M., ter Kuile F.O., Nosten F., McGready R., Asamoa K., Brabin B., Newman R.D. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis 2007;7:93-104.
- 44. Adu-Afarwuah S., Lartey A., Okronipa H., Ashorn P., Zeilani M., Baldiviez L.M., et al. Impact of small-quantity lipid-based nutrient supplement on hemoglobin, iron status and biomarkers of inflammation in pregnant Ghanaian women. Matern Child Nutr 2017;13.
- 45. Jorgensen J.M., Ashorn P., Ashorn U., Baldiviez L.M., Gondwe A., Maleta K., et al. Effects of lipid-based nutrient supplements or multiple micronutrient supplements compared with iron and folic acid supplements during pregnancy on maternal haemoglobin and iron status. Matern Child Nutr 2018;14:e12640.
- 46. Matias S.L., Mridha M.K., Young R.T., Hussain S., Dewey K.G. Daily maternal lipid-based nutrient supplementation with 20 mg iron, compared with iron and folic acid with 60 mg iron, resulted in lower iron status in late pregnancy but not at 6 months postpartum in either the mothers or their infants in Bangladesh. J Nutr 2018;148:1615-24.
- 47. Oaks B.M., Jorgensen J.M., Baldiviez L.M., Adu-Afarwuah S., Maleta K., Okronipa H., et al. Prenatal Iron Deficiency and Replete Iron Status Are Associated with Adverse Birth Outcomes, but Associations Differ in Ghana and Malawi. J Nutr 2019;149:513-21.
- 48. Martinat M., Rossitto M., Di Miceli M., Laye S. Perinatal Dietary Polyunsaturated Fatty Acids in Brain Development, Role in Neurodevelopmental Disorders. Nutrients 2021;13.
- 49. Devakumar D., Fall C.H., Sachdev H.S., Margetts B.M., Osmond C., Wells J.C., et al. Maternal antenatal multiple micronutrient supplementation for long-term health benefits in children: a systematic review and meta-analysis. BMC Med 2016;14:90.
- 50. Mertens A., Benjamin-Chung J., Colford J.M., Jr., Coyle J., van der Laan M.J., Hubbard A.E., et al. Causes and consequences of child growth faltering in low-resource settings. Nature 2023;621:568-76.
- 51. Mahmud I., Guesdon B., Kerac M., Grijalva-Eternod C.S. Mortality risk in infants receiving therapeutic care for malnutrition: A secondary analysis. Matern Child Nutr 2024:e13635.
- 52. McDonald C.M., Olofin I., Flaxman S., Fawzi W.W., Spiegelman D., Caulfield L.E., et al. The effect of multiple anthropometric deficits on child mortality: meta-analysis of individual data in 10 prospective studies from developing countries. Am J Clin Nutr 2013;97:896-901.
- 53. Verney A.M.J., Busch-Hallen J.F., Walters D.D., Rowe S.N., Kurzawa Z.A., Arabi M. Multiple micronutrient supplementation cost-benefit tool for informing maternal nutrition policy and investment decisions. Matern Child Nutr 2023;19:e13523.
- 54. Healthy Mothers Healthy Babies. Multiple Micronutrient Supplementation. Available at: https://hmhbconsortium.org/mms/. Accessed on: 18 March 2024.
- 55. Kumordzie S.M., Adu-Afarwuah S., Arimond M., Young R.R., Adom T., Boatin R., et al. Maternal and infant lipid-based nutritional supplementation increases height of Ghanaian children at 4-6 years only if the mother was not overweight before conception. J Nutr 2019;149:847-55.
- 56. Bentil H.J., Adu-Afarwuah S., Prado E.L., Arnold C.D., Hastings P.D., Guyer A.E., et al. Sustained effects of small-quantity lipid-based nutrient supplements provided during the first 1000 days on child growth at 9-11 y in a randomized controlled trial in Ghana. Am J Clin Nutr 2024;119:425-32.
- 57. WHO. WHO recommendations on antenatal care for a positive pregnancy experience. Geneva, 2016.

- 58. McDonald C.M., Wessells K.R., Stewart C.P., Dewey K.G., de Pee S., Rana R., et al. Antenatal interevention strategies providing food or cash with micronutrients to pregnant and breastfeeding women in low- and middle-income countries: a scoping review. Matern Child Nutr 2024, in submission.
- 59. International Classification of Disease 10th Revision (ICD-10). 2010. Available online at: http://www.who.int/classifications/icd/ICD10Volume2_en_2010.pdf?ua-1. Accessed on: 14 June 2021.
- 60. WHO, UNICEF Joint Monitoring Programme. Sanitation. Available at http://washdata.org/monitoring/sanitation. Accessed on: 26 August 2019.

Box 1: Outcome variables¹

¹ BMIZ, BMI-for-age z-score; HCGAZ, head circumference-for-gestational age z-score; HCZ, head circumference-for-age z-score; LAZ, length-for-age z-score; LBW, low birth weight; LGA, large-for-gestational age; LGAZ, length-for-gestational age z-score; MUAC, mid-upper arm circumference; MUACZ, mid-upper arm circumference-for-age z-score; SGA, small-for-gestational age; WAZ, weight-for-age z-score; WGAZ, weight-for-gestational age z-score; WLZ, weight-for-length z-score

² BMIZ is used as a proxy for weight-for-length z-score because the latter is not calculated for children with lengths < 45 cm (22).

Box 2: Potential effect modifiers¹

Individual-level child, maternal and household effect modifiers

Child

- Sex (female vs. male)
- Birth order (first born vs. later born)

Maternal

- Maternal height $(< 150.1$ cm vs. > 150.1 cm)²
- Maternal BMI $(< 20 \text{ kg/m}^2 \text{ vs.} \ge 20 \text{ kg/m}^2)^3$
- Maternal age $(< 25 \text{ y vs.} \ge 25 \text{ y})$
- Maternal education (no formal or incomplete primary vs. complete primary or greater)
- Baseline anemia status (Hb \geq 110 g/L vs. < 110 g/L)
- Baseline inflammation status (CRP \leq 5 mg/L and AGP \leq 1 g/L vs. not)
- Baseline malaria status (positive rapid test for malaria vs. negative test)
- Gestational age at start of supplementation $(< 14$ wk vs. > 14 wk)
- Compliance with supplementation (> 4 d/wk vs. < 4 d/wk)⁴

Household

- Household socio-economic status (\lt study median vs. $>$ study median)⁵
- Household food security (moderate to severe food insecurity vs. mild to secure)
- Sanitation (unimproved vs. improved) $⁶$ </sup>

¹ Comparisons follow the format nonreference vs. reference category. AGP, α-1-acid glycoprotein; CRP, C-reactive protein; Hb, hemoglobin. Some potential effect modifiers that were listed in the statistical analysis plan were not included: maternal marital status was dropped because of insufficient variation; maternal depression was dropped because it was evaluated only at 6 mo postpartum; source water quality was not included because there was little variation in two of the eligible trials; season at time of conception was not included because the seasonal factors that may influence pregnancy outcomes (rainy/dry, harvest/hungry, heat stress) do not always coincide and a 9-month pregnancy involves exposure to several seasons at different stages of pregnancy.

²Cutoff is -2 SD for height at 19 years of age[: https://www.who.int/growthref/hfa_girls_5_19years_z.pdf?ua=1](https://www.who.int/growthref/hfa_girls_5_19years_z.pdf?ua=1)

³When a pre-pregnancy weight measurement was not available, we estimated weight back to the 9th week of gestation using a restricted cubic spline model regressing baseline weight on gestational age at enrollment with 4 knots based on quintiles in the study's full dataset.

 4 Cutoff of > 4 d/wk chosen to accommodate the categorical variable for compliance used in the Bangladesh trial (32), which had only these choices: "did not take at all," "used to take sometimes $(1-3 \text{ d/wk})$," "used to take almost every day (4–6 d/wk),'' ''used to take regularly every day,'' and ''other.''

5 Based on a study-defined, study-specific assets index

6 Improved sanitation includes flush/pour flush to piped sewer system, septic tanks or pit latrines; ventilated improved pit latrines, composting toilets or pit latrines with slabs (60); see Supplemental Table 2, based on baseline data

Table 1. Characteristics of trials included in the individual participant data analysis1

¹IFA, iron and folic acid supplements; LNS, lipid-based nutrient supplements; MMS, multiple micronutrient supplements; SQ-LNS, small-quantity lipid-based nutrient supplement; RCT, randomized controlled trial

²In 3 study arms of the RDNS trial, women received IFA during pregnancy and for 3 months post-partum (these study arms differed in that index children received one of 3 different child supplements from 6-24 months); for the purpose of these analyses, these study arms were combined and compared with the maternal SQ-LNS arm.

³Total number enrolled in Malawi was 1391. 869 women were assigned to the complete intervention and 18-month follow-up. 522 women were assigned to pregnancy supplementation only, with simplified follow-up.

⁴Interventions noted in the table were provided to women assigned to the complete intervention cohort. Women in the simplified follow-up received supplements (SQ-LNS, IFA or MMS) from < 20 weeks of gestation to delivery only.

⁵The Women First trial provided a protein-energy supplement (in addition to SQ-LNS) to enrolled women who were either underweight or who had inadequate gestational weight gain. In 3 of the 4 study sites (Democratic Republic of the Congo, India, and Pakistan), >90% of enrolled women received this supplement in addition to SQ-LNS. Therefore, only the Guatemala site is included in these analyses (where < 10% of enrolled women received a protein-energy supplement in addition to SQ-LNS).

⁶Total number enrolled (prior to conception) was 1808 in Guatemala; the number of live births for data analysis was 651 (193 in the preconception arm, 229 in the pregnancy arm, 229 in the SOC arm).

The study arm that provided pre-conception SQ-LNS was excluded from the primary comparisons; results including this arm are presented in supplemental materials.

Birth outcome	Number of	SQ-LNS	IFA/SO	MD or RR plus	P value ³	Heterogeneity	Quality of
	participants	events	$\mathbf C$	difference in events			the
	(trials)	per 1000	events	per 1000 (95% CI) ²			evidence
			per 1000				(GRADE)
Birth weight (g)	5273(4)	\blacksquare		48.7(26.1, 71.2)	< 0.001	0.00	Moderate
Weight-for-age z score (WAZ)	5273(4)	\blacksquare	\blacksquare	0.12(0.06, 0.17)	< 0.001	0.00	Moderate
Weight-for-gestational age z-score $(WGAZ)^4$	1717(3)			0.13(0.05, 0.21)	0.001	0.31	Moderate
Low birth weight (LBW)	$\overline{5}273(4)$	168	198	0.89(0.80, 0.99)	0.033	0.00	Moderate
				-28.6 $(-51.3, -5.9)$	0.013	0.00	
Birth weight ≤ 2 kg	$\overline{5273}$ (4)	25	$\overline{35}$	0.78(0.60, 1.01)	0.062	0.00	Moderate
				-9.1 $(-18.5, 0.2)$	0.054	0.00	
Small-for-gestational age (SGA)	5181(4)	303	335	0.96(0.92, 1.01)	0.133	0.00	Moderate
				-23.0 $(-46.7, 0.7)$	0.057	0.00	
Large-for-gestational age (LGA)	4834(3)	20	23	1.00(0.61, 1.65)	0.984	0.00	Moderate
				$1.1(-3.1, 5.3)$	0.611	0.00	
Birth length (cm)	5014(4)	\blacksquare	\overline{a}	0.20(0.09, 0.31)	< 0.001	0.00	Moderate
Length-for-age z score (LAZ)	5014(4)	\blacksquare		0.11(0.06, 0.17)	< 0.001	0.00	Moderate
Length-for-gestational age z-score (LGAZ) ⁴	1460(3)	\blacksquare	L,	0.13(0.05, 0.21)	0.002	0.00	Moderate
Newborn stunting	5014(4)	138	164	$\overline{0.83}$ (0.74, 0.93)	0.001	0.00	Moderate
				-32.2 $(-51.5, -12.9)$	0.001	0.00	
Low LGAZ	4922 (4)	118	127	0.90(0.80, 1.01)	0.082	0.00	Moderate
				-12.0 $(-29.6, 5.6)$	0.182	0.00	
BMI-for-age z-score (BMIZ)	5002(4)			0.10(0.04, 0.16)	0.002	0.00	Moderate
Low BMIZ	5002(4)	123	145	0.89(0.81, 0.98)	0.022	0.26	Moderate
				$-23.6(-42.7, -4.5)$	0.015	0.20	
Head circumference (cm)	5016(4)	\blacksquare	$\overline{}$	0.11(0.04, 0.18)	0.002	0.00	Moderate
Head circumference-for-age z-score (HCZ)	5016(4)		\overline{a}	0.10(0.04, 0.16)	0.001	0.00	Moderate
Head circumference-for-gestational	1461(3)	\blacksquare	\blacksquare	0.11(0.02, 0.20)	0.019	0.00	Moderate
age z-score (HCGAZ) ⁴							
Low HCZ	5016(4)	100	118	0.85(0.75, 0.96)	0.009	0.00	Moderate
				-22.1 $(-40.5, -3.7)$	0.019	0.00	

Table 2. Main effects of maternal SQ-LNS vs IFA/SOC on birth outcomes1

1 BMIZ, BMI-for-age z-score; GRADE, Grading of Recommendations Assessment, Development and Evaluation; HCGAZ, head circumferencefor-gestational age z-score; HCZ, head circumference-for-age z-score; IFA, iron and folic acid supplement; LAZ, length-for-age z-score; LBW, low birth weight; LGA, large-for-gestational age; LGAZ, length-for-gestational age z-score; MD, mean difference; MUAC, mid-upper arum circumference; RR, relative risk; SGA, small-for-gestational age; SOC, standard of care; SQ-LNS, small-quantity lipid-based nutrient supplement; WAZ, weight-for-age z-score; WGAZ, weight-for-gestational age z-score

²For continuous outcomes, values are MDs: LNS – IFA/SOC (95% CIs). For binary outcomes, values are RRs: LNS compared with IFA/SOC (95% CIs). Difference in events per 1000 was calculated using the prevalence difference (95% CI) and multiplying by 1000.

³The P value column corresponds to the pooled main effect 2-sided superiority testing of the intervention effect estimate and 95% CI presented in the preceding column. *I***²**describes the percentage of variability in effect estimates that may be due to heterogeneity rather than chance. Roughly, $0.3 - 0.6$ may be considered moderate heterogeneity.

⁴ For continuous outcomes based on INTERGROWTH-21st standards, we excluded participants without ultrasound data for calculation of gestational age. For the corresponding binary outcomes (SGA, LGA, Low LGAZ, Low HCGAZ), we retained participants without ultrasound dating but conducted a sensitivity analysis in which they were excluded.

Table 3. Main effects of maternal SQ-LNS vs IFA/SOC on infant anthropometric outcomes at 6 mo of age1

¹GRADE, Grading of Recommendations Assessment, Development and Evaluation; HCZ, head circumference-for-age z-score; IFA, iron and folic acid supplement; LAZ, length-for-age z-score; MD, mean difference; MUAC, mid-upper arum circumference; MUACZ, mid-upper arm circumference-for-age z-score; PR, prevalence ratio; SOC, standard of care; SQ-LNS, small-quantity lipid-based nutrient supplement; WAZ, weight-for-age z-score; WLZ, weight-for-length z-score²For continuous outcomes, values are MDs: LNS – IFA/SOC (95% CIs). For binary outcomes, values are PRs: LNS compared with IFA/SOC (95% CIs). Difference in events per 1000 was calculated using the prevalence difference (95% CI) and multiplying by 1000.

¹GRADE, Grading of Recommendations Assessment, Development and Evaluation; IFA, iron and folic acid supplement; RR, relative risk; SOC, standard of care; SQ-LNS, small-quantity lipid-based nutrient supplement

²Values are RRs: LNS compared with IFA/SOC (95% CIs). Difference in events per 1000 was calculated using the prevalence difference (95% CI) and multiplying by 1000.

¹BMIZ, BMI-for-age z-score; GRADE, Grading of Recommendations Assessment, Development and Evaluation; HCGAZ, head circumferencefor-gestational age z-score; HCZ, head circumference-for-age z-score; LAZ, length-for-age z-score; LBW, low birth weight; LGA, large-forgestational age; LGAZ, length-for-gestational age z-score; MD, mean difference; MMS, multiple micronutrient supplements; MUAC, mid-upper arum circumference; RR, relative risk; SGA, small-for-gestational age; SQ-LNS, small-quantity lipid-based nutrient supplement; WAZ, weightfor-age z-score; WGAZ, weight-for-gestational age z-score

2 For continuous outcomes, values are MDs: LNS – MMS (95% CIs). For binary outcomes, values are RRs: LNS compared with MMS (95% CIs). Difference in events per 1000 was calculated using the prevalence difference (95% CI) and multiplying by 1000.

Table 6. Main effects of maternal SQ-LNS vs MMS on infant anthropometric outcomes at 6 mo of age1

¹GRADE, Grading of Recommendations Assessment, Development and Evaluation; HCZ, head circumference-for-age z-score; LAZ, length-forage z-score; MD, mean difference; MUAC, mid-upper arum circumference; MMS, multiple micronutrient supplements; MUACZ, mid-upper arm circumference-for-age z-score; PR, prevalence ratio; SQ-LNS, small-quantity lipid-based nutrient supplement; WAZ, weight-for-age z-score; WLZ, weight-for-length z-score

2 For continuous outcomes, values are MDs: LNS – MMS (95% CIs). For binary outcomes, values are PRs: LNS compared with MMS (95% CIs). Difference in events per 1000 was calculated using the prevalence difference (95% CI) and multiplying by 1000.

¹GRADE, Grading of Recommendations Assessment, Development and Evaluation; MMS, multiple micronutrient supplement; RR, relative risk; SQ-LNS, small-quantity lipid-based nutrient supplement

²Values are RRs: LNS compared with MMS (95% CIs). Difference in events per 1000 was calculated using the prevalence difference (95% CI) and multiplying by 1000.

Figure Legends

Figure 1: Study flow diagram. IFA, iron and folic acid supplements; IPD, individual participant data; MMS, multiple micronutrient supplements; RCT, randomized controlled trial; SOC, standard of care; SQ-LNS, small-quantity lipid-based nutrient supplements.

Figures 2A-F: Forest plots of effect of SQ-LNS vs IFA/SOC on birth weight, LBW, newborn LAZ, newborn HCZ, newborn BMIZ and duration of gestation. BMIZ, body mass index z-score; HCZ, head circumference-for-age z-score; IFA, iron and folic acid; LAZ, length-for-age z-score; LNS, lipid-based nutrient supplements; LBW, low birthweight; MD, mean difference; RR, relative risk; SOC, standard of care; SQ-LNS, small-quantity lipid-based nutrient supplements. Individual study estimates were generated from log-binomial regression for binary outcomes and linear regression for continuous outcomes controlling for baseline measure when available and using robust standard errors for cluster-randomized trials. Pooled estimates were generated using inverse-variance weighting with both fixed and random effects.

Figures 3A-J: Pooled effects of SQ-LNS vs IFA/SOC on birth outcomes, stratified by selected effect modifiers. LNS, lipid-based nutrient supplements; P-for-interaction, p-value for the interaction indicating the difference in effects of SQ-LNS between the two levels of the effect modifier; PR, prevalence ratio; SQ-LNS, small-quantity lipid-based nutrient supplements. Individual study estimates (not shown) were generated from log-binomial regression for binary outcomes and linear regression for continuous outcomes controlling for baseline measure when available and using robust standard errors for cluster-randomized trials. Pooled estimates (shown here) were generated using inverse-variance weighting with fixed effects.

53

Figures 4A,B: Pooled effects of SQ-LNS vs IFA/SOC on anthropometric outcomes at 6 mo of age, stratified by infant sex. LNS, lipid-based nutrient supplements; P-for-interaction, p-value for the interaction indicating the difference in effects of SQ-LNS between the two levels of the effect modifier; PR, prevalence ratio; SQ-LNS, small-quantity lipid-based nutrient supplements. Individual study estimates (not shown) were generated from log-binomial regression for binary outcomes and linear regression for continuous outcomes controlling for baseline measure when available and using robust standard errors for cluster-randomized trials. Pooled estimates (shown here) were generated using inverse-variance weighting with fixed effects.

Figures 5A-C: Forest plots of effect of SQ-LNS vs MMS on birth weight, newborn LAZ, and newborn HCZ. HCZ, head circumference-for-age z-score; LAZ, length-for-age z-score; LNS, lipid-based nutrient supplements; MD, mean difference; MMS, multiple micronutrient supplements; SQ-LNS, small-quantity lipid-based nutrient supplements. Individual study estimates were generated from log-binomial regression for binary outcomes and linear regression for continuous outcomes controlling for baseline measure when available and using robust standard errors for cluster-randomized trials. Pooled estimates were generated using inversevariance weighting with both fixed and random effects.

-0.3 0 0.3 **Difference** Favors IFA/SOC Favors SQ-LNS

B)

I² = 0.00, Tau² = 0.00

Fixed

Random

1680

3334

0.11 (0.06, 0.17)

0.11 (0.06, 0.17)

-0.5 0 0.5 **Difference** Favors IFA/SOC Favors SQ-LNS

Fixed Random W W

D)

Fixed Random W W

F)

A) Sex

B) Sex

 Ratio Favors SQ-LNS Favors IFA/SOC

Head circumference-for-age z-score (p=0.185)

Favors IFA/SOC Favors SQ-LNS

E) Maternal age

F) Maternal age

Outcome

G) Maternal inflammation

Outcome

H) Maternal inflammation

Moderate to severe

Head circumference-for-age z-score (p=0.144)

Mild to secure

Moderate to severe

MUAC (p=0.110)

552

898

555

1266

1844

1273

0.13 (0.02, 0.24)

0.05 (-0.03, 0.12)

0.16 (0.05, 0.28)

 $\begin{array}{ccc} \textcolor{blue}{\textbf{--}} \textcolor{blue}{\textbf{--}} \end{array}$

J) Food insecurity

Birth outcomes stratified by selected effect modifiers, SQ-LNS vs IFA/SOC

A)

B)

Anthropometric outcomes at 6 mo stratified by infant sex, SQ-LNS vs IFA/SOC

Birth weight

It is made available under a CC-BY 4.0 International license. medRxiv preprint doi: [https://doi.org/10.1101/2024.05.17.24307546;](https://doi.org/10.1101/2024.05.17.24307546) this version posted May 17, 2024. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted med

A)

Newborn LAZ

B)

Newborn HCZ

